Given that ADMA is known to be increased in PCOS, it is plausible that enhanced ADMA may inhibit NOS functionality in this disorder, leading to a decrease in NO production as well as associated harmful sequela such as hypertension, obesity, and IR [121–124]. This evidence concerns the gene NOS2 and obesity due to melanocortin 4 receptor deficiency.